About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.

Articles

B-type Natriuretic Peptides in the Management of Acute Heart Failure and Acute Coronary Syndromes

Citation:

Asia-Pacific Cardiology 2007;1(1):22-3

Cardiac Resynchronisation Therapy in Heart Failure Patients with Atrial Fibrillation

Citation:

European Cardiology 2010;6(2):92–5

NT-proBNP — A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure

Citation:

US Cardiology 2004;1(1):1–5

Prognostic Significance of NTproBNP in Patients with a Clinical Diagnosis of Heart Failure and Preserved Left Ventricular Systolic Function

Citation:

European Cardiovascular Disease 2007;3(1):41–2